Pharmaceutical

EMA validates BMS’s repotrectinib application to treat cancer

The EMA has validated the marketing authorisation application of Bristol Myers Squibb (BMS) for repotrectinib to treat solid tumours.

Jan 3, 2024 - 18:00
EMA validates BMS’s repotrectinib application to treat cancer
The EMA has validated the marketing authorisation application of Bristol Myers Squibb (BMS) for repotrectinib to treat solid tumours.
Read the original article

Tags:

Previous Article

Oragenics acquires neurological assets from Odyssey Health

Next Article

MediLink and Roche partner on cancer drug development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA grants ODD to Abdera’s neuroendocrine carcinoma treatment

FDA grants ODD to Abdera’s neuroendocrine carcinoma tre...

Sep 8, 2024

Bacterial infection may be ‘key event’ in common but mysterious endometriosis, study says

Bacterial infection may be ‘key event’ in common but my...

Jun 14, 2023

CVS and Walgreens plan to start dispensing abortion pill mifepristone soon

CVS and Walgreens plan to start dispensing abortion pil...

Mar 2, 2024